Amniotics AB is a biopharmaceutical company dedicated to providing unique stem cell therapeutics to patients in need.
In the News
The Bridge & Medicon Village arranged a #iställetföralmedalen digital event on work & health. https://altitudemeetings.se/jobb-halsa/ Amniotics CEO Kåre Engilde participated in discussions on Swedish virus research. https://vimeo.com/431809235
Amniotics chairman Christer Fåhraeus was recently featured in Dagens Industri. The 25 million SEK that Amniotics now takes in venture capital will be enough to investigate the possibility of using the technology against Covid-19."We intended to use stem cells for a...
https://www.mediconvillage.se/sv/amniotics-featured-tv4-their-novel-source-mscs-treat-covid-19 Amniotics was recently featured in Swedish TV4, in regard to development of our cell-therapeutic for COVID-19 diseases. Studies have shown that mesenchymal stem cells can...
COVID19 – The Corona virus pandemic calls us to action
Amniotics AB is uniquely positioned to, and we believe it is our duty to, explore a novel treatment modality for severe respiratory issues related to infections from the corona virus SARS-CoV-2. Our research and development program over the last decade geared towards treatment of severe respiratory diseases has created the knowledge and experience that may be applied to treating respiratory issues associated with COVID19. The severity of the most affected patients calls us to action. We are answering that call.